Mounjaro Injections

Information:

You may have seen information recently about the release of NICE guidance TA1026 Mounjaro (Tirzepatide) injections for managing Obesity and Overweight in Adults, as well as its use to treat Type 2 Diabetes.

Here is how this will affect patients at South Brent Health Centre.

Important: Important

From 23rd June 2025, GPs will be able to prescribe Mounjaro on the NHS to certain cohorts of patients that meet strict eligibility criteria.

This service has not yet been developed by NHS Devon and we are currently unable to initiate prescribing for Mounjaro to patients with obesity until this has been agreed and developed.

Please note

NHS Devon are advising against the independent initiation of tirzepatide (Mounjaro) prescribing for weight management until the point at which further guidance is provided.

Mounjaro prescribing in General Practice

NHS England have defined the first 3 cohorts of patients who will be able to access Mounjaro via their GP on the NHS. 

The cohorts have been decided nationally by NHS England, this is to prioritise treatment by clinical need.

The initial first 3 years will see approximately 220,000 individually nationally become eligible for treatment on the NHS. 

At a practice level, we estimate that the number of our patients eligible for Mounjaro for weight management will be less than 40. 

It is expected that after the first 3 years, the cohorts for eligiblity will expand again; however this is to be confirmed. 

The interim commissioning policy from NHS England can be viewed here: Interim commissioning guidance NICE TA1026 - Mounjaro for the management of obesity

Cohort 1: 23 June 2025

A BMI of 40 or more, or 37.5 or more if from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.

And

More than 4 of the following comorbidities:

  • Hypertension requiring blood pressure treatment
  • Dyslipidaemia (high cholesterol) or on cholesterol treatment (statin)
  • Obstructive Sleep Apnoea requiring treatment (e.g. CPAP)
  • Type 2 diabetes
  • Cardiovascular disease (ischaemic heart disease, cerebrovascular disease, peripheral arterial disease, heart failure)
Cohort 2: June 2026 (exact date to be confirmed)

A BMI of 35 or more, or 32.5 or more if from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.

And

More than 4 of the following comorbidities:

  • Hypertension requiring blood pressure treatment
  • Dyslipidaemia (high cholesterol) or on cholesterol treatment (statin)
  • Obstructive Sleep Apnoea requiring treatment (e.g. CPAP)
  • Type 2 diabetes
  • Cardiovascular disease (ischaemic heart disease, cerebrovascular disease, peripheral arterial disease, heart failure)
Cohort 3: April 2027 (exact date to be confirmed)

A BMI of 40 or more, or 37.5 or more if from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.

And

At least 3 of the following comorbidities:

  • Hypertension requiring blood pressure treatment
  • Dyslipidaemia (high cholesterol) or on cholesterol treatment (statin)
  • Obstructive Sleep Apnoea requiring treatment (e.g. CPAP)
  • Type 2 diabetes
  • Cardiovascular disease (ischaemic heart disease, cerebrovascular disease, peripheral arterial disease, heart failure)

There is local weight management support available for people living with obesity.

For details of services, please visit MyHealthDevon

Mounjaro for Type 2 Diabetes

Mounjaro is licensed to treat some patients with Type 2 diabetes under NICE TA924.

It is not suitable for everyone with Type 2 diabetes, and there are oral medications that we would prescribe first.

More information on the use of Mounjaro for Type 2 Diabetes can be found at Diabetes UK

Page last reviewed: 23 June 2025
Page created: 23 June 2025